Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe Posts Double-Digit Q2 Revenue Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe reported after the close of the market Thursday that its second-quarter revenues increased 15 percent year over year, with strong growth from both its clinical diagnostics and blood screening businesses.

The San Diego-based molecular diagnostics firm brought in total revenues of $138.6 million for the three-month period ended June 30, up from $120.5 million for the second quarter of 2009. It reported clinical diagnostics revenues of $73.9 million, up 10 percent from $67.4 million, and blood screening revenues of $55.7 million, up 22 percent from $45.8 million. Revenues for its research products and services were down 11 percent at $3.2 million versus $3.6 million.

Analysts, on average, had expected revenues of $137 million for the quarter.

Gen-Probe posted net income of $28.1 million, or $.38 per share, up from $19.8 million, or $.38 per share, for Q2 2009. The firm's non-GAAP EPS was $.52, beating analysts' consensus estimate of $.49.

"We made important progress on four US regulatory filings and three European product launches that we expect to create an important new product cycle over the balance of this year and into 2011," Gen-Probe President and CEO Carl Hull said in a statement.

Gen-Probe noted that its clinical diagnostics sales growth was driven by its Aptima Combo 2 assay for detecting chlamydia and gonorrhea, as well as products sold by Prodesse, which Gen-Probe acquired late last year for $60 million.

Its R&D spending increased nearly 4 percent to $27.1 million from $26.1 million year over year, while its SG&A expenses declined 3 percent to $30.8 million from $31.8 million.

Gen-Probe finished the quarter with $174.9 million in cash and cash equivalents, and $288.7 million in marketable securities.

The firm retained its full-year EPS guidance of between $2.12 and $2.25. However, Gen-Probe lowered the top of its revenue estimate by $3 million, providing a new estimate range of $545 million to $562 million for FY 2010.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.